Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2115 of 2580 results for methods

  1. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

  2. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

  3. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued Reference number: GID-TA10628

  4. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued Reference number: GID-TA10923

  5. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

  6. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued Reference number: GID-TA10171

  7. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued Reference number: GID-TA10193

  8. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

  9. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

  10. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  11. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

  12. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

  13. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

  14. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued Reference number: GID-TA10309

  15. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date:  13 January 2027